Butantan biomedical institute in Brazil's Sao Paulo state is in talks to sell a locally manufactured COVID-19 vaccine developed by Chinese biopharmaceutical company Sinovac Biotech (Nasdaq:SVA) to other countries in South America and Africa, Reuters news agency reported on Thursday.
The Brazilian federal government has not ordered more of Sinovac's COVID-19 vaccine doses, but Butantan has contracts to supply the vaccine directly to Brazilian states.
Currently, Butantan is producing Sinovac's CoronaVac shot using inputs imported from China. It aims to complete a factory for 100% local production by early next year.
Earlier this month, Butantan completed its contract to deliver 100 million doses of CoronaVac to Brazil's Health Ministry, without another deal in place.
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Anixa Biosciences secures US patent allowance for ovarian cancer vaccine
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
Centivax partners with Emery Pharma on universal flu vaccine
Avance Biosciences registers with CLIA program
GSK receives approval from US FDA for Penmenvy 5-in-1 meningitis vaccine
hVIVO secures GBP2m contract for final stage of hMPV characterisation study
EU approves CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine